Thrombosis
From the Journals
Ischemic stroke rates higher in young women than young men
Young women may be at a higher risk of ischemic stroke than young men, representing a “significant departure from our current scientific...
Feature
CVS Caremark formulary change freezes out apixaban
The decision doesn’t affect patients on a Medicare or Medicaid plan but hits those taking the popular anticoagulant who have select commercial...
From the Journals
Who benefits most from device PFO closure after a stroke?
Younger patients with high-risk physiological features but no vascular risk factors may benefit most from patent foramen ovale closure with a...
News from the FDA/CDC
CDC panel backs mRNA COVID vaccines over J&J because of clot risk
The risk of dying from TTS after a Johnson & Johnson shot is extremely rare.
Guidelines
ACC, AHA issue new coronary revascularization guideline
The clinical practice guideline calls for greater equity in patient care and tackles the timely issues of revascularization in stable ischemic...
From the Journals
Apixaban outmatches rivaroxaban for VTE in study
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
Conference Coverage
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Latest News
Exercise reduces arm and shoulder problems after breast cancer surgery
Study provides the best quality evidence to date in support of early exercise for women at high risk of shoulder problems after breast cancer...
Conference Coverage
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
Most outcomes remained unchanged, but follow-up imaging curtailed by the COVID-19 pandemic leaves an unfortunate gap with regard to late device-...
Conference Coverage
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MASTER DAPT subgroup analysis supports short antiplatelet course in cases of high bleeding and ischemic risk.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...